Effect of levamisol on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma.
Ten patients who had undergone repeated surgical interventions for bladder papilloma with successive recurrences within intervals of a few months, were given levamisol in weekly doses of 300 mg over a year, and were followed up for various cellular immune reactions, as well as for serum globulin and for acute-phase protein concentrations in the course of treatment. Levamisol was found to act primarily on cell-borne responsiveness. The recurrence-free intervals increased in the course of treatment. Four patients have remained free from recurrences since the start of treatment.
D000368:Aged; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods*; D007958:Leukocyte Count; D007978:Levamisole / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D010212:Papilloma / Q000276:immunology / Q000628:therapy*; D012397:Rosette Formation; D014374:Tuberculin Test; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D007074:Immunoglobulin G; D007978:Levamisole